Latest news about Cipla
Cipla
1,473.20
+6.80(+0.46%)
Company Performance:
View Company Insights1D+0.46%
1M+0.53%
6M+11.27%
1Y-5.53%
5Y+60.12%
More news about Cipla
24Jul 26
Nomura, Citi, and JPMorgan Maintain Bullish Ratings on Cipla; Target Prices Range Up to ₹1,700
Nomura, Citi, and JPMorgan have all maintained their positive ratings on Cipla following Q1 results, with target prices of ₹1,510, ₹1,700, and ₹1,600 respectively. While Q1 EBITDA margins missed estimates across the board, Cipla's retention of its FY27 margin guidance was a key reassuring factor for all three brokerages. High-value US product launches, robust India business growth, and operating leverage were identified as the primary drivers expected to support margin recovery and earnings upside.
23Jul 26
Cipla Retains 18-20% EBITDA Margin Forecast for FY27 Amid Strategic Expansion Plans
Cipla has reaffirmed its FY27 EBITDA margin forecast of 18-20% during its concall, while also outlining plans for new product launches and distribution network improvements. The company's Global CEO highlighted manufacturing diversification experience and adaptability, and the firm anticipates an upcoming reinspection of its Indore facility alongside four new products currently in development.
23Jul 26
Cipla's Sanjay Joseph ceases to be Senior Managerial Personnel
Cipla announced that Mr. Sanjay Joseph, Head – API Business, will cease to be Senior Managerial Personnel (SMP) effective July 24, 2026, due to a change in reporting structure. The Board of Directors approved this change during its meeting on July 23, 2026. The disclosure was made to major stock exchanges in compliance with SEBI regulations.
21Jul 26
GLP-1 Opportunity Set to Lift Domestic Business for Indian Pharma Firms Like Cipla and Dr. Reddy's
Indian pharmaceutical companies, including Cipla and Dr. Reddy's, are set to benefit from the GLP-1 drug opportunity in the domestic market. The expiry of semaglutide's patent in the domestic market in March has further enabled these firms to enter the segment with generic offerings. This is expected to provide a meaningful lift to their domestic business, as reported by Financial Express.
12Jul 26
Cipla assigned Crisil ESG 69 and Core ESG 66 ratings
Cipla Limited has been assigned Crisil ESG 69 and Crisil Core ESG 66 ratings by Crisil ESG Ratings & Analytics Limited following an independent assessment. The ratings were communicated on July 11, 2026. The company disclosed this information to BSE Limited and National Stock Exchange of India Limited on July 12, 2026, adhering to SEBI regulations.
09Jul 26
Cipla to discuss Q1FY27 results on July 23 earnings call
Cipla announced it will release its unaudited financial results for Q1FY27 on July 23, 2026. The company will host an earnings conference call at 1600 hrs IST to discuss the financial performance. Stakeholders can access the call via various dial-in numbers or a webcast link.
06Jul 26
Cipla records highest revenue of ₹28,000 crore in FY26
Cipla achieved its highest ever revenue of ₹28,000 crore in FY26, driven by growth in India and North America. The company reported a 21% EBITDA margin and a 13.8% PAT margin, with India business revenue crossing ₹12,500 crore. Cipla appointed M/s B S R & Co. LLP as its statutory auditor and recommended a final dividend of ₹13 per share.
30Jun 26
Cipla Records Rs. 25.83 Crores Block Trade on NSE at Rs. 1466.00 Per Share
Cipla recorded a block trade on the NSE involving approximately 1,76,199 shares at Rs. 1466.00 per share, aggregating to a total deal value of Rs. 25.83 crores. Block trades of this magnitude are typically associated with institutional investor activity and are tracked as key market events. The transaction highlights notable large-lot interest in the stock on the exchange.
26Jun 26
Cipla shareholders approve FY26 results and auditor appointment
Cipla Limited reported record revenue of INR 28,163 Cr and a PAT of INR 3,879 Cr for FY26. At the 90th AGM held on June 25, 2026, shareholders approved the financial statements, declared a dividend, and appointed M/s B S R & Co. LLP as statutory auditors. All six resolutions were passed with overwhelming majority.
26Jun 26
Cipla ESG rating revised from 68 to 64 by ESGRisks.ai
Cipla's ESG rating was revised from 68 to 64 by ESG Risk Assessments & Insights Limited following a re-evaluation of public and new information. The communication was received on June 24, 2026, and disclosed to the exchanges on June 25, 2026.
23Jun 26
US FDA Requests India's Support to Address Shortage of Key Cancer Medication Ifosfamide; Opportunity Arises for Indian Pharma Exporters
The US FDA has requested India's support to address a shortage of Ifosfamide, a critical cancer treatment medication. This presents an export opportunity for Indian pharmaceutical companies including Cipla, Zydus, Alkem, and Glenmark Life, all of which have an established presence in the US market. The development highlights India's strategic role in the global pharmaceutical supply chain and its capacity to address drug shortages in regulated markets.
20Jun 26
Cipla promoters declare no shares encumbered in FY26
Cipla Ltd promoters declared that no shares were encumbered directly or indirectly during FY26. The disclosure was made under SEBI takeover regulations and signed by Dr Y K Hamied and Mr M K Hamied.
17Jun 26
Cipla Grows Manufacturing for Respiratory and Specialty Products in India, China, and the U.S.
Cipla is expanding its manufacturing capabilities for respiratory and specialty products across India, China, and the United States. The initiative spans three major markets, reflecting the company's focus on scaling production in high-demand and complex therapeutic segments. The expansion covers both emerging and developed market supply requirements. No specific financial figures or timelines were provided in the source data.
17Jun 26
Cipla appoints Shivam Puri as CEO – One India Business effective July 1, 2026
Cipla Limited has appointed Mr. Shivam Puri as the Chief Executive Officer – One India Business and a member of the Management Council, effective July 1, 2026. Mr. Puri, currently the MD and CEO of Cipla Health Limited, brings over 23 years of experience in FMCG and healthcare sectors. Concurrently, the Board granted him 11,360 stock options under ESOS 2013-A and 51,394 ESARs under ESAR 2021, both with an exercise price of INR 2.
11Jun 26
USFDA Classifies Cipla's Goa Facility Inspection as Voluntary Action Indicated with Observations
The USFDA has classified the inspection of Cipla's Goa manufacturing facility as Voluntary Action Indicated (VAI) with observations. The VAI classification means no immediate regulatory action is required by the USFDA following the inspection. This outcome is considered favorable compared to more stringent classifications such as Official Action Indicated (OAI). The development highlights Cipla's Goa facility maintaining an acceptable regulatory standing with the USFDA.
10Jun 26
Cipla Targets 10% Revenue From Innovations Over Next Five Years, Core Business to Remain Generic Drugs
Cipla has stated that most of its core revenue will continue to come from generic drugs, reaffirming the centrality of its generics business. The company has simultaneously set a target to generate 10% of its total revenue from innovations within the next five years. This dual strategy reflects Cipla's intent to build an innovations portfolio while keeping its established generics operations as the primary revenue driver.
10Jun 26
Cipla corrects remote e-voting end date to June 24 for AGM
Cipla Limited issued a corrigendum to correct the remote e-voting end date for its 90th AGM from July 24 to June 24, 2026. The e-voting period commences on June 21, 2026, at 9:00 a.m. IST and concludes on June 24, 2026, at 5:00 p.m. IST. All other details regarding the AGM and the Integrated Annual Report for FY 2025-26 remain unchanged.
03Jun 26
Cipla to meet investors at ICICI Securities conference on June 9
Cipla Limited will engage with analysts and institutional investors at the ICICI Securities India Investor Conference in Mumbai on June 9, 2026. The meeting, disclosed under Regulation 30 of SEBI regulations, is subject to change due to unforeseen circumstances.
02Jun 26
Cipla reports lower emission intensity in FY26 sustainability filing
Cipla Limited filed its Business Responsibility and Sustainability Report for FY 2025-26, disclosing a reduction in Scope 1 and Scope 2 emission intensity to 0.25 tCO2e per ₹lakh of revenue. The report highlights 54% coverage of Zero Liquid Discharge systems, R&D expenses of ₹1,974 crore, and compliance with environmental laws verified by DNV Business Assurance India Private Limited.
29May 26
Cipla to meet investors at Citi India Conference on June 5
Cipla Limited will engage with analysts and institutional investors at the Citi India Conference on June 5, 2026, in Mumbai. The meeting will be held in person, subject to change due to unforeseen circumstances.
26May 26
Cipla Records Rs. 35.67 Crore Block Trade on NSE at Rs. 1417.00 Per Share
Cipla recorded a block trade on the National Stock Exchange valued at Rs. 35.67 crores, comprising approximately 2,51,702 shares transacted at Rs. 1417.00 per share. The trade highlights significant institutional-level interest in the stock, as block trades are large privately negotiated transactions typically executed by major institutional investors outside the open market order book.
22May 26
Cipla Fixes June 5 Record Date for INR 13 Dividend
Cipla Limited has announced June 5, 2026, as the record date for a final dividend of INR 13 per share, pending shareholder approval at the 90th AGM on June 25, 2026. For FY26, the company reported its highest-ever consolidated revenue of INR 28,163 Cr, though net profit fell to INR 3,879.23 Cr. The One India business grew 9% YoY, while North America revenue declined 13%.
14May 26
Cipla Targets $1B North America Run Rate by FY27; Analysts Divided on Outlook
Cipla's management targets a $1 billion North America run rate by end of FY27, driven by new product launches and excluding Lanreotide, with EBITDA margins guided at 18.5–20% for FY27. JPMorgan upgraded the stock to Overweight with a ₹1550 target, Citi maintained Buy with a raised ₹1700 target citing ~15% India growth and potential FY28 EBITDA margins exceeding 21%, while HSBC retained a cautious Hold at ₹1340 citing a Q4FY26 miss and Lanreotide supply concerns.
14May 26
Cipla Board Approves 90th AGM, Stock Options, and Key Appointments
Cipla Limited's Board of Directors, at its meeting on May 13, 2026, approved the convening of the 90th AGM on June 25, 2026, granted stock options and ESARs under its employee benefit schemes at an exercise price of INR 2 each, appointed M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27, and inducted Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD) effective May 18, 2026, bringing over three decades of pharmaceutical industry experience.
13May 26
Cipla Executive Warns of Rising Cost Pressures as Iran Crisis Prolongs
Cipla's executive has highlighted that the prolonged Iran crisis is causing cost escalations to seep into the company's operations. The company has so far managed freight and supply disruptions into the Middle East region through inventory management. However, the executive's remarks indicate that this cushioning effect may face increasing strain as the geopolitical situation continues.
07May 26
Cipla Opens Special Window for Physical Share Transfer
Cipla Limited announced a special window for the transfer and dematerialisation of physical shares, open until 4th February, 2027, under SEBI Circular No. HO/38/13/11(2026)-MIRSD-POD/3750/2026. Eligible shareholders with transfer deeds executed before 1st April, 2019, and original share certificates can lodge documents with KFIN Technologies Limited. Transferred shares will be issued in demat form and subject to a one-year lock-in. The company also published a notice regarding the loss of share certificates.
28Apr 26
Citigroup Maintains Buy Rating on Cipla with ₹1,530 Target Price Amid Generic Symbicort Competition
Citigroup has issued a Buy rating for Cipla with a ₹1,530 target price, citing increasing competition in the generic Symbicort market from Teva and Viatris. The brokerage emphasizes that timely US FDA approval is crucial for Cipla to capture market share and sustain growth in the competitive pharmaceutical segment.
24Apr 26
Cipla Faces US$90-100mn Revenue Risk as FDA Alert Blocks Lanreotide Supplies
Cipla's partnership with Pharmathen faces significant financial implications as FDA import alert on the Greek facility blocks Lanreotide supplies to US market. Macquarie estimates US$90-100 million revenue at risk, with earlier FY27 restart expectations now appearing unlikely due to extended compliance resolution timeline.
24Apr 26
Cipla's Lanreotide Injection Unit Expected to Generate $50-60 Million Revenue by FY27
Analysts project Cipla's Lanreotide injection manufacturing unit to generate $50-60 million in revenue during FY27, with expectations of reaching $100 million by FY28. The company operates a dedicated manufacturing facility for this specialized pharmaceutical product, positioning itself strategically in the specialty injectable market with significant growth potential.
24Apr 26
Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA
Cipla Limited announced U.S. FDA approval for its first AB-rated generic version of Ventolin HFA through regulatory filing. The Albuterol Sulfate Inhalation Aerosol will be manufactured at the company's new Massachusetts facility and launched in H1 FY 2026-27, strengthening its position in the USD 1.50 billion U.S. albuterol market.
20Apr 26
Cipla Receives Two Form 483 Observations Following U.S. FDA Inspection of Goa Plant
Cipla disclosed receiving two Form 483 observations following a U.S. FDA inspection of its Verna, Goa manufacturing facility conducted from April 6-17, 2026. The inspection was both a routine cGMP and Pre-Approval Inspection, with the company committing to address the observations within stipulated timelines while maintaining regulatory compliance standards.
16Apr 26
Cipla Schedules Q4FY26 Earnings Conference Call for May 13, 2026
Cipla Limited has scheduled an earnings conference call for May 13, 2026, at 1600 hrs IST to discuss Q4FY26 audited financial results. The announcement, made on April 16, 2026, complies with SEBI Regulation 30 requirements. The call will feature global dial-in access across multiple time zones, with the leadership team discussing financial performance and addressing investor questions. A transcript will be available post-call on the company website.
16Apr 26
Cipla Limited Issues Notice for IEPFA Second 100-Day Campaign 'Saksham Niveshak'
Cipla Limited has published newspaper advertisements on April 15, 2026, in Business Standard and Sakal regarding the IEPFA Second 100-Day Campaign 'Saksham Niveshak' to facilitate dividend claims and KYC updates. The notice, issued under SEBI Regulation 30, has been communicated to BSE, NSE, and Luxembourg Stock Exchange, with detailed information available on the company website and through appointed agencies Link Intime India Private Limited and Kfin Technologies Limited.
10Apr 26
Cipla Limited Submits Quarterly Certificate Under SEBI Depositories Regulations for Q4 FY26
Cipla Limited submitted its quarterly certificate under SEBI Depositories and Participants Regulations for Q4 FY26 ended 31st March, 2026. The certificate, confirmed by registrar KFin Technologies Limited, demonstrates compliance with dematerialization processes and regulatory requirements. The filing was made to BSE, NSE, and Luxembourg Stock Exchange on 9th April, 2026.
09Apr 26
Cipla Records ₹18.49 Crore Block Trade on NSE at ₹1228.80 Per Share
Cipla Ltd. executed a major block trade on NSE worth ₹18.49 crores involving 150,461 shares at ₹1228.80 per share. The transaction represents significant institutional activity in the pharmaceutical stock, with block trades typically indicating strategic portfolio adjustments by large investors outside regular market mechanisms.
01Apr 26
Cipla Limited Schedules Board Meeting for May 13, 2026 to Consider Q4FY26 Financial Results
Cipla Limited has scheduled a board meeting for May 13, 2026, to consider and approve Q4FY26 and annual audited financial results for the year ended March 31, 2026. The board will also deliberate on recommending a final dividend for the financial year. The company has implemented a trading window closure from April 1 to May 15, 2026, in compliance with insider trading prevention regulations.
31Mar 26
Cipla Formalizes Leadership Transition with Board Meeting Outcome and Regulatory Disclosures
Cipla has completed its leadership transition with Board approval of senior management changes and formal resignation of Umang Vohra as Director. The company categorized Saurabh Gambhir and Satyavan Manikani as Senior Management Personnel under new MD Achin Gupta's leadership, following successful postal ballot results with strong shareholder support across all resolutions.
28Mar 26
Cipla Opens Special Window for Physical Share Transfer and Dematerialisation Following SEBI Directive
Cipla Limited has opened a special window for physical share transfer and dematerialisation following SEBI Circular dated January 30, 2026. The window remains open until February 4, 2027, with specific eligibility criteria for shareholders. Transferred shares will be issued in demat form only with a one-year lock-in period. Eligible shareholders must submit documents to KFIN Technologies Limited in Hyderabad.
27Mar 26
Cipla Announces Resignation of Global Chief Scientific Officer Pradeep Bhadauria
Cipla has announced the resignation of Mr. Pradeep Bhadauria, Global Chief Scientific Officer and Management Council member, effective March 31, 2026. Bhadauria, employed through wholly owned subsidiary Cipla USA Inc., is leaving to pursue interests outside the company. The pharmaceutical company communicated this leadership change to stock exchanges through a regulatory filing dated March 26, 2026.
25Mar 26
UBS Cuts Cipla Target Price to Rs 1400 Amid Supply Headwinds
UBS has cut Cipla's target price to Rs 1400 from Rs 1750 while maintaining a neutral rating. The brokerage acknowledges the company's strong product pipeline supporting medium-term growth but cites near-term supply headwinds, including Lanreotide issues, as limiting factors. These operational challenges are weighing on the immediate outlook despite longer-term pharmaceutical sector potential.
19Mar 26
Cipla Board Approves Leadership Changes and $100 Million EU Investment Plan
Cipla announced significant corporate developments including the designation of P R Ramesh as Vice-Chairman effective April 1, 2026, and Robert Stewart's decision not to seek re-appointment. The board approved a $100 million investment in Cipla (EU) Limited for onward financial assistance to InvaGen Pharmaceuticals Inc., and the merger with wholly-owned subsidiary Inzpera Healthsciences Limited to streamline operations and achieve efficiencies.
18Mar 26
Cipla Allots 1,954 Equity Shares Under Employee Stock Option Schemes
Cipla Limited has allotted 1,954 fully paid-up equity shares under its Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021, as approved by the Operations and Administrative Committee on 18th March, 2026. The allotment increases the company's paid-up share capital to INR 1,61,55,65,262, comprising 80,77,82,631 equity shares of INR 2 face value each. The company has notified all relevant stock exchanges and depositories in compliance with SEBI regulations.
17Mar 26
Cipla Records Rs. 57.04 Crore Block Trade on NSE at Rs. 1289.80 Per Share
Cipla recorded a significant block trade on NSE worth Rs. 57.04 crores involving approximately 442,266 shares at Rs. 1289.80 per share. The transaction reflects institutional investor activity and demonstrates continued interest in the pharmaceutical major's stock through the block deal mechanism.
10Mar 26
Cipla USA Starts Recall of Lanreotide Injection Batches, Leading to Short-Term Supply Issues
Cipla's US subsidiary has announced a recall of unexpired Lanreotide Injection batches, resulting in temporary supply disruption. The recall follows extensive discussions with partner Pharmathen International and represents the latest in a series of regulatory communications filed since January 2026.
04Mar 26
Cipla Forms 60:40 Joint Venture with Kemwell Biopharma for Biologics Development
Cipla has entered into a strategic 60:40 joint venture with Kemwell Biopharma Private Limited to develop and commercialize biologic products. The partnership involves a significant investment commitment of up to ₹100 million from both partners according to their ownership ratios, marking Cipla's major expansion into the biologics segment through collaboration with Kemwell's specialized CDMO capabilities.
02Mar 26
Cipla: New Subsidiary Established in Saudi Arabia
Cipla Limited has established a new wholly owned subsidiary, Cipla Middle East Company, in Saudi Arabia through its UK entity Cipla (EU) Limited. The subsidiary, incorporated on 1st March, 2026, will focus on pharmaceutical manufacturing, distribution, and holding marketing authorizations in the Kingdom of Saudi Arabia, representing Cipla's strategic expansion into the Middle Eastern pharmaceutical market.
26Feb 26
Cipla ESG Rating Revised Down from 66 to 65 for FY2024-25 Following US Subsidiary Product Recall
Cipla Limited has disclosed a revision in its ESG rating for FY 2024-25 from 66 to 65 by NSE Sustainability Ratings & Analytics Limited. The pharmaceutical company attributes this potential downgrade to a product recall by its wholly owned US subsidiary, Cipla USA Inc., in January 2026. The rating communication was received on 25th February, 2026, and formally disclosed to stock exchanges on 26th February, 2026, in compliance with SEBI regulations.
23Feb 26
Cipla Announces Postal Ballot for Achin Gupta's Appointment as Managing Director and Global CEO
Cipla Limited has issued a postal ballot notice seeking shareholder approval for appointing Mr Achin Gupta as Managing Director and Global CEO with effect from 1st April, 2026. The proposed compensation includes INR 10 crore annual salary, variable bonuses, and stock-based benefits capped at INR 60 crore over five years. The e-voting period runs from 24th February to 25th March, 2026, with results expected by 30th March, 2026. The ballot also includes re-appointment of Mr P R Ramesh as Independent Director for a second term.
21Feb 26
Cipla: USFDA Inspection at Subsidiary Pharmathen's Facility Classified as OAI
Cipla Limited disclosed that the USFDA has classified the cGMP inspection at its subsidiary Pharmathen International S.A.'s facility in Rodopi, Greece as Official Action Indicated (OAI). The facility serves as a supply partner for Lanreotide Injection to Cipla USA Inc. and the classification indicates significant regulatory issues requiring corrective action.
10Feb 26
Cipla GST Department Inspection Concludes With No Material Impact
Cipla Limited has successfully concluded GST Department inspection proceedings that began on February 5, 2026 and ended on February 7, 2026. The company provided full cooperation and all necessary documentation to authorities, with no official orders issued and no material impact on financials or operations confirmed.
10Feb 26
Cipla's US Subsidiary InvaGen Receives 2 USFDA Observations Following Pre-Approval Inspection
Cipla Limited's wholly owned US subsidiary InvaGen Pharmaceuticals received 2 inspection observations in Form 483 from the USFDA following a Pre-Approval Inspection conducted from February 2nd to 9th, 2026 at its Hauppauge, New York manufacturing facility. The company has committed to working closely with the USFDA to address these observations comprehensively within the stipulated timeframe and has notified stock exchanges as per regulatory requirements.
28Jan 26
Cipla Allots 8,879 Equity Shares Under Employee Stock Option Schemes
Cipla Limited allotted 8,879 equity shares under its Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 on January 28, 2026. The shares, with a face value of INR 2 each, were issued following approval by the Operations and Administrative Committee. This allotment increased the company's paid-up share capital to INR 1,61,55,61,354, comprising 80,77,80,677 total equity shares. The company has informed BSE, NSE, and Luxembourg Stock Exchange about this development in compliance with SEBI regulations.
27Jan 26
Cipla Records Rs. 15.48 Crore Block Trade on NSE at Rs. 1298.90 Per Share
Cipla Ltd. executed a significant block trade on NSE worth Rs. 15.48 crores involving approximately 119,140 shares at Rs. 1298.90 per share. The transaction indicates substantial institutional investor activity in the pharmaceutical major's stock through off-market dealing mechanisms.
23Jan 26
Cipla Explores Semaglutide Generics Market Entry, Partners with Eli Lilly for Mounjaro Launch
Cipla is exploring entry into the semaglutide generics market while partnering with Eli Lilly to launch Mounjaro under the Yurpeak brand. This dual strategy positions the company to capture opportunities across both generic and branded segments in the growing diabetes care market, demonstrating a comprehensive approach to expanding its therapeutic portfolio.
23Jan 26
Cipla Shares Decline 3.5% Amid High Trading Volume Despite Strong Financial Performance
Cipla shares declined 3.5% to ₹1,322.40 amid high trading volume, despite strong financial performance showing quarterly sales growth to ₹7,589 crores in September 2025. The pharmaceutical company demonstrated consistent annual growth with sales increasing from ₹19,159 crores in March 2021 to ₹27,547 crores in March 2025, while net profit more than doubled to ₹5,291 crores. Key financial metrics indicate healthy operations with improved profit margins, strong balance sheet position, and a debt-to-equity ratio of 0.00.
23Jan 26
Cipla Limited Board Approves Key Managerial Personnel Changes Effective April 2026
Cipla Limited's Board of Directors approved changes in Key Managerial Personnel on January 23, 2026, effective April 1, 2026. The updates include contact details for four key positions: Mr. Achin Gupta as Managing Director and Global CEO, Mr. Ashish Adukia as Global CFO, Mr. Rajendra Chopra as Company Secretary, and Ms. Meera Vanjari as Global General Counsel. The company has notified BSE, NSE, and Luxembourg Stock Exchange while maintaining full regulatory compliance under SEBI Listing Regulations.
23Jan 26
Cipla Board Approves Re-appointment of P R Ramesh as Independent Director for Second Term
Cipla Limited's Board has approved Mr P R Ramesh's re-appointment as Independent Director for a second five-year term from July 2026 to June 2031, subject to shareholder approval. The decision was made during a board meeting on January 23, 2026. Mr Ramesh, who has served as Independent Director since July 2021 and currently chairs the Audit Committee, brings over 45 years of experience and serves on boards of several leading companies including Air India, L&T, and Nestlé India.
23Jan 26
Cipla Co-CEO Expects Upcoming Launches to Cushion Revlimid Revenue Impact
Cipla's Co-CEO has announced that upcoming product launches are expected to help offset revenue challenges related to Revlimid. This strategic communication reflects the company's proactive approach to portfolio management and revenue diversification in the oncology segment.
23Jan 26
Cipla Q3 Net Profit Falls 57% to ₹6.76 Billion, Misses Analyst Estimates
Cipla's third quarter consolidated net profit dropped 57% year-on-year to ₹6.76 billion from ₹15.70 billion, significantly missing analyst estimates of ₹11.30 billion. The pharmaceutical company's actual results came in approximately 40% below market consensus, indicating substantial operational challenges during the reporting period.
20Jan 26
Cipla Partners ImmunoACT to Launch CAR-T Therapy for Blood Cancers in Africa
Cipla Ltd has partnered with ImmunoACT on January 20 to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell therapy, for blood cancer treatment in South Africa, Algeria and Morocco through its subsidiary Medpro Pharmaceutica. The therapy targets patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma and B-cell Acute Lymphoblastic Leukaemia, having shown high efficacy in over 500 patients in India. However, the company faces US FDA regulatory observations regarding contamination prevention and manufacturing controls at one of its facilities.
19Jan 26
Cipla's $120-150M Lanreotide Product Faces Extended U.S. Recall, Resupply Unlikely
Cipla is experiencing a significant regulatory challenge with the Class II recall of its Lanreotide injection in the U.S. market, which Nomura identifies as one of the company's top American products generating $120-150 million in annual sales. The situation has worsened with the assessment that resupply is unlikely in H1 FY27, suggesting complex quality issues that require extensive remediation efforts.
16Jan 26
Cipla Shares Slide 5% After Temporary Halt In Key Drug Manufacturing
Cipla's stock declined significantly after the company disclosed a temporary production halt of Lanreotide, one of its top three US products, following USFDA inspection observations at its Greek manufacturing partner. The technical indicators show bearish sentiment with RSI at oversold levels and trading below key moving averages.
16Jan 26
Cipla Pauses Lanreotide Production as Zydus Gets FDA Approval for Eltrombopag Tablets
Cipla Ltd temporarily halted Lanreotide injection production due to remediation at supply partner Pharmathen International's Greece facility, with resumption expected in H1 FY27. Zydus Lifesciences received FDA approval for Eltrombopag tablets in four strengths for treating thrombocytopenia. Biocon successfully raised ₹4,150 crore through QIP at ₹368.35 per share to fund Mylan Inc. stake buyout in Biocon Biologics.
15Jan 26
USFDA Issues Form 483 to Pharmathen's Greece Plant; Cipla Pauses Lanreotide Production Until FY27
The USFDA has issued a Form 483 to Pharmathen's Greece manufacturing facility, leading to a temporary suspension of lanreotide production. Cipla expects supply to resume in the first half of FY27 following resolution of regulatory compliance issues.
13Jan 26
Cipla Shares Drop 2% as US FDA Approves Rival's Generic Advair Inhaler
Cipla shares fell nearly 2% on January 13 following US FDA approval of Aurobindo Pharma's generic Advair inhaler, touching a nine-month low of ₹1,436.60. Citi Research called this a "marginal negative" for Cipla, projecting $30-40 million annual US revenue for Aurobindo's version. Despite the competitive pressure, analysts expect Cipla's own generic Advair approval soon, potentially contributing $50 million to US revenue by FY27.
12Jan 26
Cipla Records ₹68.52 Crore Block Trade on NSE at ₹1,451.50 Per Share
Cipla Limited executed a significant block trade on NSE worth ₹68.52 crores involving approximately 472,059 shares at ₹1,451.50 per share. The transaction represents substantial institutional trading activity in the pharmaceutical major's stock, indicating active participation by large investors in the healthcare sector.
09Jan 26
Cipla Records ₹15.11 Crore Block Trade on NSE at ₹1,460.80 Per Share
Cipla Ltd. executed a major block trade on NSE worth ₹15.11 crores involving approximately 103,457 shares at ₹1,460.80 per share. This substantial transaction indicates significant institutional activity and strategic investment interest in the pharmaceutical company's stock.
07Jan 26
Cipla Evaluates US FDA Form 483 Observations on Supply Partner Pharmathen
Cipla Ltd clarified FDA inspectional observations on supply partner Pharmathen International SA following stock exchange queries. The FDA inspection at Pharmathen's Greece facility from November 10-21, 2025, resulted in nine Form 483 observations including contamination control issues, sterile condition deficiencies, and laboratory control shortcomings. Pharmathen manufactures lanreotide injection for Cipla's US operations, and the company is evaluating the impact while shares declined 4.28% to ₹1,465.30.
07Jan 26
Cipla Shares Fall 4% After USFDA Issues Form 483 to Partner Pharmathen Facility
Cipla shares declined 4% following FDA's Form 483 issuance to manufacturing partner Pharmathen's Rodopi facility, highlighting nine serious cGMP compliance violations including microbiological contamination risks and data integrity concerns. The facility manufactures Lanreotide, Cipla's largest US product, raising supply chain disruption concerns among investors.
06Jan 26
Cipla Records ₹15.81 Crore NSE Block Trade at ₹1528.30 Per Share
Cipla Ltd. recorded a significant NSE block trade worth ₹15.81 crores involving 103,426 shares at ₹1528.30 per share. The transaction represents substantial institutional activity and provides insights into large investor sentiment toward the pharmaceutical company. Block trades typically indicate portfolio adjustments by major stakeholders and can influence market sentiment while providing liquidity for large-scale transactions.
05Jan 26
Cipla Records ₹76.53 Crore Block Trade on NSE at ₹1,514.40 Per Share
Cipla executed a major block trade on NSE worth ₹76.53 crores involving approximately 505,366 shares at ₹1,514.40 per share. The transaction highlights significant institutional activity and demonstrates strong liquidity in the pharmaceutical major's equity.
30Dec 25
Cipla Announces Superannuation of Global Chief People Officer Dr Raju Mistry
Cipla Limited announced the superannuation of Dr Raju Mistry, Global Chief People Officer and Senior Management Personnel, effective December 31, 2025. The disclosure was made under Regulation 30 of SEBI Listing Regulations to BSE, NSE, and Luxembourg Stock Exchange. The company will announce his successor in due course, with the filing signed by Company Secretary Rajendra Chopra on December 30, 2025.
22Dec 25
Cipla ESG Rating Improves to 68 from SEBI-Registered Provider ESGRisks.ai
Cipla Limited has received an updated ESG rating of 68 from ESGRisks.ai, a SEBI-registered ESG rating provider, representing an improvement from its previous rating of 60. The communication was received on December 22, 2025, and disclosed in compliance with SEBI regulations to multiple stock exchanges including BSE, NSE, and Luxembourg Stock Exchange.
19Dec 25
Pfizer Signs Exclusive 5-Year Marketing Deal With Cipla For Four Key Brands
Pfizer Limited has signed an exclusive 5-year marketing and distribution agreement with Cipla Limited for four key pharmaceutical brands in India. The partnership covers respiratory, anti-inflammatory, gastroenterology and anti-infective medicines, with Pfizer continuing manufacturing while Cipla handles distribution through its extensive network.
18Dec 25
360ONE WAM Allots 2.13 Lakh Equity Shares Under Employee Stock Option Scheme
360ONE WAM Limited has successfully allotted 2,12,637 equity shares to employees under its Employee Stock Options Scheme following approval by the Nomination and Remuneration Committee. The allotment increased the company's paid-up share capital to ₹40.53 crores, reflecting strong employee engagement in equity participation programs.
11Dec 25
Cipla Launches Yurpeak (Tirzepatide) for Treatment of Obesity and Type 2 Diabetes
Cipla has launched Yurpeak (Tirzepatide), a new treatment for obesity and Type 2 diabetes. The product contains Tirzepatide as its active ingredient and targets both metabolic conditions simultaneously. This launch strengthens Cipla's pharmaceutical portfolio in the metabolic disorders segment and provides healthcare providers with an additional treatment option for patients managing obesity and Type 2 diabetes.
10Dec 25
Cipla Officially Launches Yurpeak (Tirzepatide) for Diabetes and Obesity Treatment
Cipla has officially launched Yurpeak® (tirzepatide) in India under a marketing and distribution agreement with Eli Lilly, targeting obesity and type 2 diabetes treatment. The innovative dual agonist therapy will be available in six strengths using KwikPen® device format, with comprehensive patient support programs and nationwide distribution strategy.
18Nov 25
Eli Lilly Secures Regulatory Approval for Donanemab in India
Pharmaceutical giant Eli Lilly has received regulatory approval to market Donanemab in India, marking a significant milestone in its global expansion. This development grants Eli Lilly access to one of the world's largest pharmaceutical markets, potentially expanding its global footprint and revenue streams. The approval could introduce new treatment options for patients in India and impact the competitive landscape in the relevant therapeutic area.
07Nov 25
Eli Lilly's Mounjaro Tops India's Pharma Market with ₹1 Billion Monthly Sales via Cipla Partnership
Mounjaro, a diabetes medication by Eli Lilly, has become India's top revenue-generating drug with ₹1 billion in monthly sales in October. This success is attributed to Eli Lilly's partnership with Cipla for distribution in India. Mounjaro, or tirzepatide, is a weekly injectable for adults with type 2 diabetes. The drug's success highlights the growing demand for effective diabetes treatments in India and showcases the potential of innovative medications in addressing critical health needs in the country.
03Nov 25
Cipla Achieves Record Quarterly Revenue of ₹7,589 Crores, Appoints New CEO
Cipla achieved its highest-ever quarterly revenue of ₹7,589 crores, an 8% year-on-year growth, with a 25% EBITDA margin. Achin Gupta will become the new CEO effective January 1st. The One-India business grew 7% with strong performance in key therapies. In North America, Cipla leads the U.S. albuterol MDI market with a 22% share and entered the biosimilars market. The company partnered with Eli Lilly to enter the obesity care segment. Cipla revised its full-year EBITDA margin guidance to 22.75% - 24% due to increased R&D investments and reduced contribution from generic Revlimid.
03Nov 25
Cipla Expands Pediatric Portfolio with INR 110.65 Crore Acquisition of Inzpera Healthsciences
Cipla Limited has agreed to acquire a 100% stake in Inzpera Healthsciences Limited for approximately INR 110.65 crores in cash. Inzpera specializes in pediatric pharmaceutical and wellness products. The acquisition aims to combine Inzpera's product portfolio with Cipla's distribution network, enhancing Cipla's presence in the pediatric healthcare segment. The deal, valued at an enterprise value of INR 120 crores, is expected to complete within a month. Inzpera, founded in 2016, reported a turnover of INR 26.75 crores in FY 2024-25.
30Oct 25
Cipla Unveils Ambitious Plan to Launch 7 New Products by 2026; CEO Confirms Eli Lilly's Adequate Mounjaro Supply
Cipla announced plans to introduce seven new products by 2026, including four respiratory assets and three peptide products. The company aims to launch Gadvair in Q4 FY26. CEO Vohra confirmed sufficient supply of Eli Lilly's Mounjaro diabetes medication. Cipla reported strong Q2 FY26 financial results with revenue up 8% YoY to ₹7,589 Cr. The company maintains market leadership with Foracort as the #1 brand and Albuterol holding 22% U.S. market share.
30Oct 25
Cipla Announces Strategic Leadership Transition: Achin Gupta to Succeed Umang Vohra as MD & GCEO in 2026
Cipla Limited has announced a leadership transition plan effective April 1, 2026. Umang Vohra, current MD & GCEO, will not seek re-appointment after his term ends on March 31, 2026. Achin Gupta, currently GCOO, will assume the role of MD & GCEO. Gupta will be appointed as MD & GCEO Designate on January 1, 2026, before fully taking over on April 1, 2026, for a 5-year term. Additionally, Meera Vanjari will become Global General Counsel and Senior Management Personnel from April 1, 2026. The transition aims to ensure continuity and drive Cipla's future growth.
30Oct 25
Cipla Reports 4% Growth in Q2 Net Profit to Rs 1,351 Crore, Beating Estimates
Cipla's Q2 results show a 4% increase in net profit to Rs 1,351.00 crore and 8% growth in revenue to Rs 7,589.00 crore. EBITDA improved marginally by 0.5% to Rs 1,895.00 crore, but the EBITDA margin declined to 25.00%. The company faces challenges in the US market due to increased competition for Revlimid Generic and fewer regulatory approvals. The pharmaceutical sector overall is experiencing margin pressures with projected revenue growth of 7-10% and earnings growth of 4-5%. Investors are focusing on the performance of new oncology drugs, GST impact, and updates on the Indore facility reinspection.
23Oct 25
Cipla Expands Diabetes and Obesity Treatment Options with Yurpeak Launch in India
Cipla Limited has entered a strategic partnership with Eli Lilly and Company (India) to introduce Yurpeak, a second brand of tirzepatide, in India. Yurpeak, like Lilly's Mounjaro, is a prescription medication for type 2 diabetes and obesity management. Eli Lilly will manufacture the product, while Cipla will handle distribution and promotion. The medication will be available in various strengths as a multi-dose, single-patient-use prefilled pen for once-weekly administration. This collaboration aims to expand access to innovative treatments for diabetes and obesity across India, addressing significant health concerns in the country. The launch is pending regulatory approvals.
25Sept 25
Cipla Shares Worth Rs. 51.05 Crores Traded in NSE Block Deal
Cipla experienced a significant block trade on the NSE, involving 331,705 shares at ₹1,539.10 per share, totaling ₹51.05 crores. This large-scale transaction highlights substantial investor interest in the pharmaceutical company. The impact on Cipla's stock price and trading patterns will be closely monitored by investors and analysts in the coming days.
27Aug 25
Cipla USA Recalls Over 20,000 Packs of Asthma Medication Due to Stability Issues
Cipla USA, Inc. has initiated a recall of 20,352 packs of Albuterol Sulfate Inhalation Aerosol in the United States. The recall was prompted by failed stability specifications during routine quality control tests. The FDA has classified it as a Class III recall, indicating low risk of adverse health consequences. The recall affects a medication used for treating asthma and COPD. Cipla initiated the recall on July 24, demonstrating a proactive approach to quality control and patient safety.
05Aug 25
Cipla's Bommasandra Facility Receives VAI Classification from USFDA
Cipla Limited's manufacturing facility in Bommasandra, Bengaluru, has been classified as Voluntary Action Indicated (VAI) by the USFDA following a cGMP inspection from May 26 to May 30. The decision was communicated on August 4. VAI classification indicates that while some issues were identified, they don't warrant immediate regulatory action. Cipla can address these voluntarily while continuing operations at the facility. The company has disclosed this development to stock exchanges in compliance with SEBI regulations.
28Jul 25
Cipla Shares Surge 6% on Strong Quarterly Results, Brokerages Raise Target Prices
Cipla's shares surged 6% to Rs 1,575.00 following impressive quarterly earnings. The company reported a 10% YoY increase in Profit After Tax to Rs 1,298.00 crore and a 4% rise in revenue to Rs 6,957.00 crore. EBITDA grew 4% to Rs 1,778.00 crore, with a slight margin decline to 25.60%. Cipla maintains a strong balance sheet with Rs 10,838.00 crore in cash reserves. Multiple brokerages have revised their target prices upward, with Antique setting the highest at Rs 1,875.00. Analysts highlight Cipla's strong product pipeline, particularly in respiratory products, and its target of $1 billion in US sales by FY27.
28Jul 25
Cipla Shares Dip Despite Strong Q1 Performance and Record India Business
Cipla's Q1 consolidated net profit increased by 10% to ₹1,298.00 crore, surpassing analyst estimates. The India Business segment crossed ₹3,000.00 crore for the first time in an opening quarter, growing 6% year-on-year. North America business generated $226 million in quarterly revenue. Despite positive results, Cipla's shares fell 0.39% to ₹1,526.50. Revenue increased by 4.58% to ₹7,095.60 crore, while EBITDA grew 6.05% to ₹1,916.30 crore.
25Jul 25
Cipla Reports Strong Q1 FY26 Results, Eyes GLP-1 Market Expansion
Cipla Limited reported robust Q1 FY2026 results with total revenue of INR 6,957.47 crore, up 4% YoY. EBITDA reached INR 1,778.00 crore with a 25.6% margin, and net profit increased 10% YoY to INR 1,298.00 crore. Growth was seen across all major markets. The company plans to enter the GLP-1 market, aiming to launch Semaglutide upon patent expiry. With a strong cash reserve of INR 108.38 billion, Cipla is well-positioned for future investments and expansions.
25Jul 25
Cipla's Q1 Net Profit Surges 10% to ₹13 Billion, Beating Estimates
Cipla Limited reported strong Q1 financial results, with consolidated net profit rising 10% to ₹13.00 billion, surpassing analyst estimates. Revenue increased to ₹69.60 billion, and EBITDA grew to ₹17.78 billion. The 'One India' strategy achieved record Q1 sales exceeding ₹30.00 billion. Albuterol ranked No. 1 in North America with a 19.50% market share, while the South Africa private market grew at 1.5 times the market rate.
24Jul 25
Cipla Q1 Results Preview: Mixed Performance Expected with US Business Headwinds
Cipla Limited is expected to report mixed Q1 earnings on July 25. Revenue growth projections range from 3.6% to 9% YoY, driven by strong domestic sales but offset by declining US generics business. Net profit estimates range from ₹1,140.00 crore to ₹1,380.00 crore. US revenue is projected to decline 12-13% YoY due to lower gRevlimid prices, while domestic formulations segment is forecasted to grow 8-9% YoY. EBITDA margins are expected to contract by about 100 basis points YoY. Key focus areas include US business trajectory, pricing trends, India business recovery, new product launches, and cost management.
21Jul 25
Cipla Strengthens Respiratory Healthcare with ₹5 Crore Investment in Icaltech Innovations
Cipla Limited has announced a strategic investment of ₹5 crore to acquire a 20% stake in Icaltech Innovations Private Limited, a Bangalore-based medical devices company specializing in respiratory care diagnostics. The investment involves subscribing to 1,50,820 optionally convertible preference shares and 1 equity share. This move aims to strengthen Cipla's position in respiratory healthcare and expand its diagnostic solutions portfolio. The collaboration is expected to leverage synergies between Cipla's pharmaceutical expertise and Icaltech's medical device technologies. Icaltech has shown significant growth, with its turnover increasing from ₹1.28 crore in FY 2022-23 to ₹6.70 crore projected for FY 2024-25.
10Jul 25
Cipla Ltd. Shares in Focus: Block Trade Worth Rs. 61.27 Crores Executed
A block trade of 416,640 Cipla Ltd. shares was executed on the National Stock Exchange (NSE) at Rs. 1,470.60 per share, totaling Rs. 61.27 crores. This substantial transaction has drawn attention to the prominent Indian pharmaceutical company, potentially indicating strategic moves by large market players. While the parties involved remain undisclosed, such trades can sometimes signal shifts in institutional holdings or changing perspectives on the company's prospects.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent PharmaceuticalsCipla
Zydus Life Science
Lupin
Mankind Pharma
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
1,990.50
(-0.53%)
8,056.00
(+2.82%)
5,122.80
(+5.15%)
1,473.20
(+0.46%)
1,126.80
(+1.05%)
2,415.00
(-0.26%)
2,469.60
(-4.13%)
1,816.20
(+1.96%)
1,148.10
(+0.29%)
1,580.20
(+0.25%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
